Comparative Pharmacology
Head-to-head clinical analysis: GASTROMARK versus OSMOVIST 190.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROMARK versus OSMOVIST 190.
GASTROMARK vs OSMOVIST 190
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
None Documented
None Documented
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent